Volume 9, 2 Issues, 2022 ISSN: 2212-6988 (Online) ISSN: 2212-697X (Print)
This journal supports open access
Increase Visibility of your Article
We are keen to ensure your research study gets maximum reach and attention among the research and professional communities. Following are certain recommendations that may help you enhance the visibility of your work.
Create ORCID ID and update your list of publications on ORCID
Sign up on KUDOS website. Claim and explain your article. Share it with the research and professional community online via KUDOS
Generate Shareable-PDF of the explanation you have given for your article on Kudos. Share this PDF via ResearchGate, Academia, Mendeley and other research platforms.
Explain your work on Wikipedia
Create your own webpage and publish updates on freely accessible articles
Present your work at Conferences (you can let us know which conferences you are attending and we can provide you with promotional material for your articles)
Create accounts on Social Media platforms, for e.g. Blogging websites, Facebook, Twitter, LinkedIn, Youtube, Gmail and other Google web applications. Publish posts to project your research on these media
Join LinkedIn Groups relevant to your area of research and publish posts to project your article to the Group members
These activities can help you spread your work among the relevant audience, and provide the opportunity to increase readership and citations.
Giulio Francia Department of Biological Sciences The University of Texas El Paso, TX (USA) Biography
Biography of Giulio Francia
Dr. Francia began his career by undertaking a PhD with Dr. Ian Hart at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. After his PhD, he trained with Dr. Robert Kerbel in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. He is now Assistant Professor at The University of Texas at El Paso, where he is attempting to set up a research program that is internationally recognized for pioneering new cancer therapeutic ideas, and for generating in vivo models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those he has already established.